Prokidney Corp. (PROK) intrinsic value & 10-year financials
Prokidney Corp. (PROK) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 1075.0% a year to $893.0K, with an average return on invested capital of 154.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.33
- Market cap
- $81.8M
- Revenue (FY2025)
- $893.0K
- Revenue growth (7-yr CAGR)
- 1075.0%
- ROIC (10-yr avg)
- 154.3%
- Free cash flow (FY2025)
- -$135.3M
PROK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $893.0K | -$69.0M | — | -$135.3M | -18477.8% | 14.9% |
| FY2024 | $76.0K | -$61.2M | — | -$155.9M | -241678.9% | 16.2% |
| FY2023 | $0 | -$35.5M | — | -$124.3M | — | 11.0% |
| FY2022 | $0 | -$148.1M | -$0.23 | -$78.9M | — | 19.2% |
| FY2021 | — | -$55.1M | — | -$55.5M | — | 710.1% |
| FY2020 | — | -$26.7M | — | -$30.6M | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PROKIDNEY CORP. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PROKIDNEY CORP. returns on capital have been average, hovering around 13.7% ROIC over the decade.
PROKIDNEY CORP. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PROKIDNEY CORP. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-37.23 per share.